Atrial fibrillation (AF) is the most common sustained arrhythmia in the western world. It is
associated with increased morbidity and mortality and decreased quality of life. The absence …

Atrial fibrillation (AF) is associated with significant morbidity and mortality. It is also a
progressive disease secondary to continuous structural remodelling of the atria due to AF …

Atrial fibrillation (AF) is the most common cardiac arrhythmia in clinical practice, with over 3
million cases in the USA and 4.5 million in Europe. Its incidence is rising rapidly, and the …

Atrial fibrillation is the most common arrhythmia in clinical practice. Ion channel blocking
agents are often characterized by limited long‐term efficacy and several side effects. In …

Inadequacies in current therapies for atrial fibrillation have made new drug development
crucial. Conventional antiarrhythmic drugs increase the risk of ventricular proarrhythmia. In …

Continued growth in atrial fibrillation (AF)–related morbidity and mortality raises the demand
for therapies to prevent or delay AF onset and progression. The transition from paroxysmal …

Atrial fibrillation (AF) is generally considered a progressive disease, typically evolving from
paroxysmal through persistent to 'permanent'forms, a process attributed to electrical and …

Failure of current pharmacological therapy for atrial fibrillation in maintaining sinus rhythm
may be due to structural atrial remodeling caused by inflammation and fibrosis. Upstream …

The therapy or prevention of atrial fibrillation (AF) is defined as upstream therapy when
conducted with the use of drugs, eg, angiotensin-converting enzyme inhibitors (ACEIs) …

Atrial fibrillation (AF) causes important mortality and morbidity on a population-level. So far,
we do not have the means to prevent AF or AF-related complications adequately. Therefore …